Week in Review: The Latest from PhRMA

Priscilla VanderVeer   |     August 7, 2015   |   SHARE THIS

week-in-reviewGAO: Prescription Drugs Are Just 2% of Medicaid Spending: The Government Accountability Office reported that fee-for-service drugs accounted for only 1.7 percent of Medicaid expenditures in 2014. Prescription medicines represent a small share of Medicaid spending and are not a main driver of Medicaid spending growth. Find out more here.

The Future of Clinical Pathways: With appropriate use, clinical pathways can improve patient outcomes, but the future is uncertain. As providers and payers increasingly utilize clinical pathways, it is important that these pathways serve as a resource for clinicians and not a restriction on the care patients receive. Check it out here.

Prescription Drug Prices Fall Significantly Over Time: Biopharmaceutical companies invest in innovative research to bring new treatments to patients, and over time those medicines become available as lower-cost generic copies. Learn about the impact of generics here.

Health Care Policy Developments: Learn about recent legislative and legal action that seeks to improve both patient care and the efficiency of the US healthcare system here.

Medicare Monday: Did you know four out of five Part D prescriptions are generic? Since Part D’s implementation, generic utilization reached 84 percent in 2013. Learn more here.

Priscilla VanderVeer

Priscilla VanderVeer Priscilla VanderVeer Priscilla VanderVeer is a vice president, public affairs, at PhRMA. Ms. VanderVeer has more than 15 years of experience communicating important health care issues to a wide variety of audiences, including medical, health and patient advocates; policymakers and opinion-leaders; and the general public. At PhRMA, Ms. VanderVeer leads the development and execution of communications strategies and activities for the organization’s key state advocacy priorities. She lives in Annapolis, Maryland with her husband, Ken and their two dogs: Bea Arthur, a tiny 5 lb. Maltese and Henry, a slightly larger-than-average Yorkshire Terrier.

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates